Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor,” published in the January 2025 issue of Allergy ...

Now, Honigberg and colleagues describe an orally available, potent and selective inhibitor of the B-cell receptor (BCR) signalling molecule Bruton's tyrosine kinase (BTK), which shows promising ...

a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas, Haematologica (2024). DOI: 10.3324/haematol.

Figure 4: Impaired antigen receptor–activated B cell proliferation and humoral responses in Vav-deficient mice. Figure 5: Vav-2 in BCR signaling and tyrosine phosphorylation in Vav-1 −/− Vav ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...